Sara J. Adair

1.8k total citations
32 papers, 972 citations indexed

About

Sara J. Adair is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Sara J. Adair has authored 32 papers receiving a total of 972 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 9 papers in Molecular Biology and 7 papers in Cancer Research. Recurrent topics in Sara J. Adair's work include Pancreatic and Hepatic Oncology Research (10 papers), Microfluidic and Bio-sensing Technologies (7 papers) and Cancer Cells and Metastasis (5 papers). Sara J. Adair is often cited by papers focused on Pancreatic and Hepatic Oncology Research (10 papers), Microfluidic and Bio-sensing Technologies (7 papers) and Cancer Cells and Metastasis (5 papers). Sara J. Adair collaborates with scholars based in United States, Netherlands and Italy. Sara J. Adair's co-authors include Todd W. Bauer, Kevin T. Hogan, J. Thomas Parsons, Edward B. Stelow, Dustin M. Walters, Bryce Lowrey, Jayme B. Stokes, Nathan S. Swami, Carlos Honrado and Sarbajeet Nagdas and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Sara J. Adair

28 papers receiving 961 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sara J. Adair United States 15 474 393 222 187 182 32 972
Noor Jailkhani United States 10 355 0.7× 330 0.8× 222 1.0× 137 0.7× 58 0.3× 15 747
Lidia Moyano‐Galceran Sweden 12 265 0.6× 330 0.8× 162 0.7× 80 0.4× 155 0.9× 15 679
Christopher J. Tape United Kingdom 20 548 1.2× 637 1.6× 236 1.1× 126 0.7× 235 1.3× 36 1.3k
Loucinda Carey United States 6 362 0.8× 457 1.2× 76 0.3× 188 1.0× 176 1.0× 7 793
Michael den Bakker Netherlands 7 750 1.6× 869 2.2× 244 1.1× 231 1.2× 242 1.3× 10 1.6k
Kam Sprott United States 12 756 1.6× 376 1.0× 156 0.7× 127 0.7× 276 1.5× 31 1.2k
Julia V. Burnier Canada 21 592 1.2× 408 1.0× 174 0.8× 98 0.5× 318 1.7× 73 1.2k
Mario A. Shields United States 16 504 1.1× 609 1.5× 143 0.6× 105 0.6× 235 1.3× 25 1.1k
Denarda Dangaj Laniti Switzerland 15 367 0.8× 703 1.8× 544 2.5× 128 0.7× 186 1.0× 31 1.1k
Martine H. van Miltenburg Netherlands 9 677 1.4× 573 1.5× 275 1.2× 77 0.4× 266 1.5× 9 1.2k

Countries citing papers authored by Sara J. Adair

Since Specialization
Citations

This map shows the geographic impact of Sara J. Adair's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sara J. Adair with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sara J. Adair more than expected).

Fields of papers citing papers by Sara J. Adair

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sara J. Adair. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sara J. Adair. The network helps show where Sara J. Adair may publish in the future.

Co-authorship network of co-authors of Sara J. Adair

This figure shows the co-authorship network connecting the top 25 collaborators of Sara J. Adair. A scholar is included among the top collaborators of Sara J. Adair based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sara J. Adair. Sara J. Adair is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Myers, Paul J., Sara J. Adair, Jason R. Pitarresi, et al.. (2024). A Histone Methylation–MAPK Signaling Axis Drives Durable Epithelial–Mesenchymal Transition in Hypoxic Pancreatic Cancer. Cancer Research. 84(11). 1764–1780. 14 indexed citations
3.
Mandal, Arabinda, Jagathpala Shetty, Walter C. Olson, et al.. (2024). Cancer-oocyte SAS1B protein is expressed at the cell surface of multiple solid tumors and targeted with antibody-drug conjugates. Journal for ImmunoTherapy of Cancer. 12(3). e008430–e008430. 1 indexed citations
4.
Adair, Sara J., et al.. (2023). Interrogating the CD27:CD70 axis in αCD40-dependent control of pancreatic adenocarcinoma. Frontiers in Cell and Developmental Biology. 11. 1173686–1173686. 1 indexed citations
5.
Salahi, Armita, Carlos Honrado, John H. Moore, et al.. (2023). Supervised learning on impedance cytometry data for label-free biophysical distinction of pancreatic cancer cells versus their associated fibroblasts under gemcitabine treatment. Biosensors and Bioelectronics. 231. 115262–115262. 17 indexed citations
6.
7.
Honrado, Carlos, Sara J. Adair, John H. Moore, et al.. (2021). Apoptotic Bodies in the Pancreatic Tumor Cell Culture Media Enable Label‐Free Drug Sensitivity Assessment by Impedance Cytometry. Advanced Biology. 5(8). e2100438–e2100438. 19 indexed citations
8.
Wei, Xiaolong, Jiekun Yang, Sara J. Adair, et al.. (2020). Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic cancer cells. Proceedings of the National Academy of Sciences. 117(45). 28068–28079. 60 indexed citations
9.
Kane, William J., Sara J. Adair, Sarbajeet Nagdas, et al.. (2020). Abstract PO-007: PRMT5 inhibition sensitizes pancreatic cancer to gemcitabine in orthotopic and metastatic murine models. Cancer Research. 80(22_Supplement). PO–7. 2 indexed citations
10.
Nagdas, Sarbajeet, Jennifer A. Kashatus, Sarah Pollock, et al.. (2019). Drp1 Promotes KRas-Driven Metabolic Changes to Drive Pancreatic Tumor Growth. Cell Reports. 28(7). 1845–1859.e5. 102 indexed citations
11.
McGrath, John S., Carlos Honrado, John H. Moore, et al.. (2019). Electrophysiology-based stratification of pancreatic tumorigenicity by label-free single-cell impedance cytometry. Analytica Chimica Acta. 1101. 90–98. 53 indexed citations
12.
Szlachta, Karol, Cem Kuscu, Turan Tufan, et al.. (2018). CRISPR knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug response. Nature Communications. 9(1). 4275–4275. 57 indexed citations
13.
Michaels, Alex D., Timothy E. Newhook, Sara J. Adair, et al.. (2017). CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer. Clinical Cancer Research. 24(6). 1415–1425. 81 indexed citations
14.
Newhook, Timothy E., James Lindberg, Sara J. Adair, et al.. (2016). Adjuvant Trametinib Delays the Outgrowth of Occult Pancreatic Cancer in a Mouse Model of Patient-Derived Liver Metastasis. Annals of Surgical Oncology. 23(6). 1993–2000. 11 indexed citations
15.
Lindberg, James, Timothy E. Newhook, Sara J. Adair, et al.. (2014). Co-Treatment with Panitumumab and Trastuzumab Augments Response to the MEK Inhibitor Trametinib in a Patient-Derived Xenograft Model of Pancreatic Cancer. Neoplasia. 16(7). 562–571. 25 indexed citations
16.
Newhook, Timothy E., Edik M. Blais, James Lindberg, et al.. (2014). A Thirteen-Gene Expression Signature Predicts Survival of Patients with Pancreatic Cancer and Identifies New Genes of Interest. PLoS ONE. 9(9). e105631–e105631. 27 indexed citations
17.
18.
Stokes, Jayme B., Sara J. Adair, Jill K. Slack‐Davis, et al.. (2011). Inhibition of Focal Adhesion Kinase by PF-562,271 Inhibits the Growth and Metastasis of Pancreatic Cancer Concomitant with Altering the Tumor Microenvironment. Molecular Cancer Therapeutics. 10(11). 2135–2145. 185 indexed citations
19.
20.
Carr, Tiffany, et al.. (2007). Immunological profiling of a panel of human ovarian cancer cell lines. Cancer Immunology Immunotherapy. 57(1). 31–42. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Noor Jailkhani Breakdown of academic impact, for papers by Lidia Moyano‐Galceran Breakdown of academic impact, for papers by Christopher J. Tape Breakdown of academic impact, for papers by Loucinda Carey Breakdown of academic impact, for papers by Michael den Bakker Breakdown of academic impact, for papers by Kam Sprott Breakdown of academic impact, for papers by Julia V. Burnier Breakdown of academic impact, for papers by Mario A. Shields Breakdown of academic impact, for papers by Denarda Dangaj Laniti Breakdown of academic impact, for papers by Martine H. van Miltenburg
Rankless by CCL
2026